Abstract:The DNA damage response (DDR) encompasses the detection and repair of DNA lesions and is fundamental to the maintenance of genome integrity. Germline DDR alterations underlie hereditary chromosome instability syndromes by promoting the acquisition of pathogenic structural variants in hematopoietic cells, resulting in increased predisposition to hematologic malignancies. Also frequent in hematologic malignancies are somatic mutations of DDR genes, typically arising from replication stress triggered by oncogene activation or deregulated tumor proliferation that provides a selective pressure for DDR loss. These defects impair homology-directed DNA repair or replication stress response, leading to an excessive reliance on error-prone DNA repair mechanisms that results in genomic instability and tumor progression. In hematologic malignancies, loss-of-function DDR alterations confer clonal growth advantage and adverse prognostic impact, but may also provide therapeutic opportunities. Selective targeting of functional dependencies arising from these defects could achieve synthetic lethality, a therapeutic concept exemplified by inhibition of poly(ADP-ribose) polymerase or the ATR-CHK1-WEE1 axis in malignancies harboring the BRCAness phenotype or genetic defects that increase replication stress. Furthermore, the role of DDR defects as a source of tumor immunogenicity, as well as their impact on the crosstalk between DDR, inflammation and tumor immunity are increasingly recognized, thus providing rationale for combining DDR modulation with immune modulation. The nature of the DDR-immune interface and the cellular vulnerabilities conferred by DDR defects may nonetheless be disease-specific and remain incompletely understood in many hematologic malignancies. Their comprehensive elucidation will be critical for optimizing therapeutic strategies to target DDR defects in these diseases.-

Targeting DNA damage response pathways in cancer

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Targeting the DNA damage response in hematological malignancies

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Advancing cancer therapy: new frontiers in targeting DNA damage response

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Abstract IA017: Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors

Targeting DNA damage response deficiency in the treatment of breast cancer

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons

The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy

DNA Damage Response Inhibitors: an Avenue for TNBC Treatment